Evidence map›Paper›PMID 38586364›Full record

ArticleHeliyon2024

Sebaceous hyperplasia of the eyelid: A comprehensive case report and literature review.

Mingshen Ma, Rui Liu, Jing Li, Hang Yang, Runzi Yang, Jianmin Ma

Abstract readCase Reports
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mingshen MaDepartment of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, 100027, Beijing, China.
Rui LiuDepartment of Ocular Oncology, Beijing Tongren Hospital, Capital Medical University, 100730, Beijing, China.
Jing LiDepartment of Ocular Oncology, Beijing Tongren Hospital, Capital Medical University, 100730, Beijing, China.
Hang YangInstitute of Human Nutrition, Columbia University, New York, NY, 10032, United States.
Runzi YangDepartment of Ocular Oncology, Beijing Tongren Hospital, Capital Medical University, 100730, Beijing, China.
Jianmin MaDepartment of Ocular Oncology, Beijing Tongren Hospital, Capital Medical University, 100730, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Sebaceous gland hyperplasia of the eyelids, known as adenomatoid or pseudoadenomatous hyperplasia, is a rare benign condition. Optimal management strategies for this specific type of eyelid tumor require further investigation. Case presentation: The patient presented with a 21-year history of a progressively enlarged mass in the right lower eyelid. Previous treatments, including laser photocoagulation and surgical excision, have failed to prevent recurrence. The mass, characterized by a firm texture and low mobility, has raised concerns regarding malignancy. However, histopathological examination following surgical excision identified the mass as sebaceous gland hyperplasia. The patient's medical history was notable for benign gastrointestinal and intestinal polyps with no evidence of malignancy. Conclusions: A final diagnosis of eyelid sebaceous gland hyperplasia was established after surgical excision and comprehensive histopathological analyses. The patient's successful recovery without recurrence over a three-month follow-up period post-surgery highlights the efficacy of the surgical approach and the use of intraoperative frozen section pathological examination.

Indexed as

Case reportEyelid sebaceous gland hyperplasiaIntraoperative pathological examinationSurgical excision

Identifiers

PMID38586364
PMCPMC10998099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.